Innovative Solutions for drug resistance
Transforming drug resistance with cutting-edge research.
Innovative Solutions for drug resistance
Transforming drug resistance with cutting-edge research.
Transforming drug resistance with cutting-edge research.
Transforming drug resistance with cutting-edge research.
Our team brings deep experience in cancer pharmacology, non-apoptotic biology, targeted delivery, and translational modeling. We work with clinical collaborators to ensure that our programs answer patient-level questions.
Celyra Therapeutics is a biotechnology company advancing therapies to overcome drug resistance in cancer. The company’s platform combines non-apoptotic cell-death inducers with targeted delivery to eliminate resistant tumor cells that standard treatments miss. Celyra’s pipeline includes lead programs in triple-negative breast cancer and resistant solid tumors, supported by biomarker-guided development. Celyra collaborates with academic and industry partners to accelerate translation from discovery to clinic.
We are proud of the impact that our biotech products and therapies have had on patient care. Our products have been used to diagnose and treat a wide range of health conditions, from cancer to infectious diseases. We are committed to continuing to develop innovative solutions that improve patient outcomes.
Celyra targets a large unmet need with a differentiated approach. We focus resources on programs with resistance biology, tractable biomarkers, delivery platforms and combinations that can move quickly.
We advance lead assets through key preclinical value inflection and partner for later development. We also out-license delivery modules and co-create programs with pharma and leading cancer centers.
Our small-molecule probes activate non-apoptotic death pathways that remain available even when apoptosis is offline. These programs include necroptosis-like signaling, paraptosis-like vacuolization, ferroptosis-like lipid damage, and other regulated mechanisms. By engaging alternative execution routes, we broaden the options for killing resistant cells.
We design delivery systems that prefer resistant tumor phenotypes. Platforms include ligand-guided nanoparticles and carriers that exploit tumor nutrient pathways and macropinocytosis for uptake and endolysosomal release.
Cancer often learns to ignore therapy. Apoptosis-based drugs lose power when tumors disable the very pathways those drugs rely on. Patients pay the price with relapse and progression. We address resistance head-on by engaging alternative death programs and by delivering therapy directly to the cells that do not respond.
We pair non-apoptotic cell-death inducers with selective delivery systems. This two-part approach aims to:
Hits resistant tumors where apoptosis fails.
Concentrates therapy in the cells that matter.
Engineered for rational pairing with standard regimens and immunotherapy.
At Celyra Therapeutics, we strive to leverage innovative biotechnology solutions to enhance human health. Our vision is to transform scientific discoveries into effective therapies that address unmet medical needs.
Celyra Therapeutics
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.